Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer

Cancer Science

Volumn 97, Issue 2, 2006, Pages 148-154

  Yokouchi, Hiroshi ^a,b   Chamoto, Kenji ^a   Wakita, Daiko ^a   Noguchi, Daisuke ^a   Yamazaki, Koichi ^b   Dosaka Akita, Hirotoshi ^c   Nishimura, Masaharu ^b   Ikeda, Hiroaki ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN; PEPTIDE; T LYMPHOCYTE RECEPTOR; TETRAMER;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FLOW CYTOMETRY; IN VIVO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; SENSITIVITY AND SPECIFICITY; TRANSGENIC MOUSE; TUMOR IMMUNITY; VACCINATION;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; TUMOR CELLS, CULTURED;

EID: 33644908236     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00149.x     Document Type: Article

References (24)

1. Howard MC, Spack EG, Choudhury K, Greten TF, Schneck JP. MHC-based diagnostics and therapeutics - clinical applications for disease genes. Immunol Today 1999; 20: 161-5.
2. Altman JD, Moss PAH, Goulder PJR et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-6.
3. Bousso P, Casrouge A, Altman JD et al. Individual variations in the murine T-cell response to a specific peptide reflect variability in naïve repertoires. Immunity 1998; 9: 169-78.
4. Lee PP, Savage PA, Fong L et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med 1999; 5: 677-85.
5. Yee C, Riddell SR, Greenberg PD. In vivo tracking of tumor-specific T cells. Cur Opin Immmunol 2001; 13: 141- 6.
6. 264-272 peptide in the circulation of patients with head and neck cancer. Cancer Res 2002; 62: 3521-9.
7. Palmowski M, Salio M, Dunbar RP, Cerundolo V. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol Rev 2002; 188: 155-63.
8. Cohen CJ, Denkberg G, Schiffenbauer YS et al. Simultaneous monitoring of binding to and activation of tumor-specific T lymphocytes by peptide-MHC. J Immunol Meth 2003; 277: 39-52.
9. Rosato A, Santa SD, Zoso A et al. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 env product of an endogenous retrovirus. Cancer Res 2003; 63: 2158-63.
10. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell response to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 2003; 9: 641-9.
11. Rivoltini L, Castelli C, Carrabba M et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 2003; 171: 3467-74.
12. Zajac P, Oertli D, Marti W et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 2003; 14: 1497-510.
13. + T cells. Clin Cancer Res 2004; 10: 668-80.
14. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64: 4973-9.
15. Cochran JR, Cameron TO, Stern LJ. The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity 2000; 12: 241-50.
16. Cohen CJ, Denkberg G, Schiffenbauer YS et al. Simultaneous monitoring of binding to and activation of tumor-specific T lymphocytes by peptide-MHC. J Immunol Meth 2003; 277: 39-52.
17. Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190: 617-27.
18. Bodinier M, Peyrat M, Tournay C et al. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nature Med 2000; 6: 707-10.
19. Xu XN, Purbhoo MA, Chen N et al. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using α3 domain mutants of MHC class I/peptide complex. Immunity 2001; 14: 591-602.
20. Huang JF, Yand Y, Spulveda H et al. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science 1999; 286: 952-4.
21. Dustin ML, Miller JM, Ranganath S et al. TCR-mediated adhesion of T-cell hybridomas to planar bilayers containing purified MHC class II/peptide complexes and receptor shedding during detachment. J Immunol 1996; 157: 2014-21.
22. Valitutti S, Müller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Science 1995; 375: 148-51.
23. Itoh Y, Hemmer B, Martin R, Germain RN. Serial TCR engagement and down-modulation Ry peptide: MHC molecule ligands: relationship to the quality of individual TCR signaling events. J Immunol 1999; 162: 2073-80.
24. Lee KH, Wang E, Nielsen MB et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163: 6292-300.